MCID: DYS009
MIFTS: 42

Dysthymic Disorder

Categories: Mental diseases

Aliases & Classifications for Dysthymic Disorder

MalaCards integrated aliases for Dysthymic Disorder:

Name: Dysthymic Disorder 12 41 14 69
Dysthymia 12 72 51

Classifications:



External Ids:

Disease Ontology 12 DOID:12139
ICD10 32 F34.1
ICD9CM 34 300.4
MeSH 41 D019263
NCIt 46 C34562
SNOMED-CT 64 192384008 78667006
UMLS 69 C0013415

Summaries for Dysthymic Disorder

Disease Ontology : 12 A mood disorder that involves the presence of a low mood almost daily over a span of at least two years.

MalaCards based summary : Dysthymic Disorder, also known as dysthymia, is related to atypical depressive disorder and mental depression. An important gene associated with Dysthymic Disorder is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Circadian rythm related genes and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and spinal cord, and related phenotype is muscle.

Wikipedia : 72 Dysthymia, now known as persistent depressive disorder (PDD), is a mood disorder consisting of the same... more...

Related Diseases for Dysthymic Disorder

Diseases related to Dysthymic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Related Disease Score Top Affiliating Genes
1 atypical depressive disorder 30.5 GATA3 HTR7 MAOA SLC6A4
2 mental depression 30.2 GATA3 HTR2A HTR7 MAOA SLC6A4
3 anxiety 30.1 HTR2A MAOA SLC6A4
4 personality disorder 30.0 HTR2A MAOA SLC6A4
5 generalized anxiety disorder 29.8 HTR2A MAOA SLC6A4
6 attention deficit-hyperactivity disorder 29.7 HTR2A MAOA SLC6A4
7 obsessive-compulsive disorder 29.6 HTR2A MAOA SLC6A4
8 borderline personality disorder 29.5 HTR2A MAOA SLC6A4
9 panic disorder 29.4 HTR2A MAOA SLC6A4
10 major depressive disorder 29.3 CRY2 GATA3 HTR2A MAOA SLC6A4
11 alcohol dependence 28.9 HTR2A HTR7 MAOA SLC6A4
12 schizoid personality disorder 10.3 HTR2A PIR
13 coronary artery vasospasm 10.2 HTR2A HTR7
14 aging 10.2
15 drug-induced mental disorder 10.2 HTR2A HTR7
16 drug psychosis 10.2 HTR2A HTR7
17 alzheimer disease 5 10.0 HTR2A SLC6A4
18 separation anxiety disorder 10.0 HTR7 PIR
19 alcoholic psychosis 10.0 HTR2A SLC6A4
20 periodic limb movement disorder 10.0 HTR2A SLC6A4
21 bruxism 10.0 HTR2A SLC6A4
22 social phobia 10.0 MAOA SLC6A4
23 alcohol use disorder 10.0
24 oppositional defiant disorder 10.0 MAOA SLC6A4
25 neurotic disorder 9.9
26 obsessive-compulsive personality disorder 9.9 PIR SLC6A4
27 antisocial personality disorder 9.9 MAOA SLC6A4
28 postpartum depression 9.9 MAOA SLC6A4
29 bipolar i disorder 9.9 HTR2A SLC6A4
30 pathological gambling 9.8 HTR2A MAOA SLC6A4
31 episodic pain syndrome, familial, 1 9.8
32 alacrima, achalasia, and mental retardation syndrome 9.8
33 paranoid schizophrenia 9.8 HTR2A MAOA SLC6A4
34 early-onset schizophrenia 9.8 HTR2A MAOA SLC6A4
35 conduct disorder 9.8 MAOA SLC6A4
36 serotonin syndrome 9.8 HTR2A MAOA SLC6A4
37 chronic pulmonary heart disease 9.8 HTR7 SLC6A4
38 post-traumatic stress disorder 9.8 HTR2A MAOA SLC6A4
39 mood disorder 9.8 HTR2A MAOA SLC6A4
40 intermittent explosive disorder 9.8 HTR7 SLC6A4
41 sudden infant death syndrome 9.7 HTR2A MAOA SLC6A4
42 phobic disorder 9.7 MAOA PIR SLC6A4
43 agoraphobia 9.7 MAOA PIR SLC6A4
44 psychosexual disorder 9.7 HTR2A HTR7 SLC6A4
45 brunner syndrome 9.7 HTR7 MAOA SLC6A4
46 substance abuse 9.7 MAOA SLC6A4
47 irritable bowel syndrome 9.6 HTR7 SLC6A4
48 endogenous depression 9.6 GATA3 HTR2A MAOA SLC6A4
49 bulimia nervosa 1 9.5 HTR2A HTR7 MAOA SLC6A4
50 disease of mental health 9.5 HTR2A HTR7 MAOA SLC6A4

Comorbidity relations with Dysthymic Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 54)


Active Peptic Ulcer Disease Acute Cystitis
Adjustment Disorder Anxiety
Atrophic Gastritis Atypical Depressive Disorder
Avoidant Personality Disorder Benign Essential Hypertension
Borderline Personality Disorder Bronchitis
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Conversion Disorder Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dyskinesia of Esophagus Esophagitis
Familial Atrial Fibrillation Generalized Anxiety Disorder
Generalized Atherosclerosis Heart Disease
Histrionic Personality Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Iron Deficiency Anemia
Irritable Bowel Syndrome Ischemic Heart Disease
Major Depressive Disorder Mitral Valve Disease
Mood Disorder Narcissistic Personality Disorder
Obsessive-Compulsive Disorder Obsessive-Compulsive Personality Disorder
Opioid Addiction Oral Candidiasis
Orthostatic Intolerance Osteoarthritis
Osteoporosis Paralytic Ileus
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Personality Disorder Post-Traumatic Stress Disorder
Postinflammatory Pulmonary Fibrosis Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Dysthymic Disorder:



Diseases related to Dysthymic Disorder

Symptoms & Phenotypes for Dysthymic Disorder

MGI Mouse Phenotypes related to Dysthymic Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.02 CRY2 GATA3 HTR2A MFSD8 SLC6A4

Drugs & Therapeutics for Dysthymic Disorder

Drugs for Dysthymic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4 58-18-4 6010
2
Testosterone Approved, Investigational Phase 4 58-22-0 6013
3
Citalopram Approved Phase 4,Phase 2,Phase 3 59729-33-8 2771
4
Sertraline Approved Phase 4,Phase 2,Phase 3 79617-96-2 68617
5
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
6
Fluoxetine Approved, Vet_approved Phase 4,Phase 2,Phase 3 54910-89-3 3386
7
Norepinephrine Approved Phase 4,Phase 2,Phase 3 51-41-2 439260
8
Bupropion Approved Phase 4,Phase 2,Phase 3 34911-55-2, 34841-39-9 444
9
Armodafinil Approved, Investigational Phase 4 112111-43-0
10
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
11
Imipramine Approved Phase 4 50-49-7 3696
12
Paroxetine Approved, Investigational Phase 4,Phase 2 61869-08-7 43815
13
Donepezil Approved Phase 4 120014-06-4 3152
14
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
15 Anabolic Agents Phase 4
16 Androgens Phase 4
17 Antineoplastic Agents, Hormonal Phase 4
18 Hormone Antagonists Phase 4
19 Hormones Phase 4
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
21 Testosterone 17 beta-cypionate Phase 4
22
Testosterone enanthate Phase 4 315-37-7 9416
23 Testosterone undecanoate Phase 4
24 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3
26 Antiparkinson Agents Phase 4,Phase 2
27 Autonomic Agents Phase 4,Phase 2,Phase 1
28 Cholinergic Agents Phase 4,Phase 2,Phase 1
29 Cholinergic Antagonists Phase 4,Phase 2
30 Muscarinic Antagonists Phase 4,Phase 2
31 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3
33 Parasympatholytics Phase 4,Phase 2
34 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
35 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1
36
Serotonin Phase 4,Phase 2,Phase 3 50-67-9 5202
37 Serotonin Agents Phase 4,Phase 2,Phase 3
38 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 3
39 Analgesics Phase 4
40 Dopamine Agents Phase 4,Phase 2,Phase 3
41 Duloxetine Hydrochloride Phase 4
42 Monoamine Oxidase Inhibitors Phase 4
43 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 2,Phase 3
44 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2,Phase 3
45 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
46 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3
47 Central Nervous System Stimulants Phase 4,Phase 1,Phase 2
48 Cytochrome P-450 CYP3A Inducers Phase 4
49 Wakefulness-Promoting Agents Phase 4
50 Desvenlafaxine Succinate Phase 4 386750-22-7

Interventional clinical trials:

(show top 50) (show all 77)

# Name Status NCT ID Phase Drugs
1 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
2 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4 escitalopram and sertraline
3 Duloxetine Treatment in Elderly With Dysthymia Completed NCT01852383 Phase 4 Duloxetine
4 Wellbutrin XL for Dysthymic Disorder Completed NCT00225251 Phase 4 bupropion XL
5 Escitalopram in the Treatment of Dysthymic Disorder, Double Blind Completed NCT00220701 Phase 4 Lexapro (escitalopram)
6 Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Completed NCT00518986 Phase 4 armodafinil;placebo
7 Duloxetine for Chronic Depression: a Double-blind Study Completed NCT00360724 Phase 4 Duloxetine (Cymbalta)
8 Desvenlafaxine vs. Placebo Treatment of Chronic Depression Completed NCT01537068 Phase 4 Desvenlafaxine;Placebo
9 Project to Improve Symptoms and Mood in People With Spinal Cord Injury Completed NCT00592384 Phase 4 venlafaxine XR;placebo
10 Treatment of Depression Following Multiple Brain Tests Completed NCT00296777 Phase 4 Escitalopram;Bupropion;Imipramine
11 Dichotic Listening as a Predictor of Medication Response in Depression Completed NCT00296725 Phase 4 Fluoxetine;Imipramine
12 Are Two Antidepressants a Good Initial Treatment for Depression? Completed NCT00296712 Phase 4 escitalopram + bupropion
13 Dichotic Listening as a Predictor of Medication Response in Depression Completed NCT00404755 Phase 4 escitalopram;bupropion;imipramine
14 Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction Completed NCT00159809 Phase 4 Viagra (Sildenafil citrate)
15 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
16 A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression Completed NCT00296699 Phase 4 Duloxetine
17 Combination Treatment Study for Memory Impairment and Depression Completed NCT01658228 Phase 4 Donepezil;Placebo;Citalopram;Venlafaxine
18 Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults Recruiting NCT01973283 Phase 4 Antidepressant Medication
19 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Active, not recruiting NCT00182533 Phase 4 Sertraline;Placebo
20 Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction Terminated NCT00398632 Phase 4 Duloxetine
21 A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults Withdrawn NCT01942187 Phase 4 Aripiprazole;Bupropion
22 A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior Completed NCT01447602 Phase 3
23 A Stepped Care Model of Adolescent Depression Treatment in Primary Care Completed NCT01443715 Phase 2, Phase 3
24 Treatment of Adolescent Suicide Attempters (TASA) Completed NCT00080158 Phase 2, Phase 3 fluoxetine;sertraline;citalopram;escitalopram;bupropion;mirtazapine;venlafaxine;lithium
25 Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder Completed NCT00707980 Phase 3 Vortioxetine
26 A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND} Active, not recruiting NCT02358343 Phase 3 Antidepressant Drug Therapy
27 Effects of Therapist Behavior on the Treatment of Depressed Adolescents Unknown status NCT00073359 Phase 1, Phase 2
28 A Study of Omega-3 as a Treatment for Major Depression Unknown status NCT00238758 Phase 2 Omega-3 Polyunsaturated Fatty Acids
29 The Efficacy of Parent Involvement in the Treatment of Adolescent Depression Completed NCT00883519 Phase 1, Phase 2
30 New Approaches to Cocaine Abuse Medications (A) - 6 Completed NCT00000271 Phase 2 Desipramine;Placebo
31 Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
32 Computerized Information-Processing Bias Retraining in Depressed Adolescents Completed NCT01147913 Phase 2
33 A Safety, Efficacy and Tolerability Study of SEP-225289 Completed NCT00584974 Phase 2 SEP-225289;SEP-225289;Venlafaxine;placebo
34 Group Interpersonal Psychotherapy for Depressed Adolescents in School-based Clinics Completed NCT00270244 Phase 2
35 Group Therapy for Women Prisoners With Comorbid Substance Use and Depression Completed NCT00606996 Phase 2
36 Bringing What Works to Youth in Corrections: A Trauma Intervention Completed NCT01560728 Phase 1, Phase 2
37 Smoking Cessation for Depressed Smokers Active, not recruiting NCT00494728 Phase 1, Phase 2 Nicotine Replacement Therapy
38 eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients Enrolling by invitation NCT02458690 Phase 2 Antidepressant Medications
39 Interpersonal Psychotherapy for Depressed Adolescents and Parents Completed NCT00619411 Phase 1
40 Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression Completed NCT00356304 Phase 1
41 Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression Unknown status NCT01473615
42 Epidemiological Study for Psychiatric Disorder Among Children and Adolescents Unknown status NCT02707848
43 Desvenlafaxine Monotherapy in Dysthymia Completed NCT01948895 Desvenlafaxine
44 Duloxetine for the Treatment of Dysthymia Completed NCT00185575 duloxetine
45 Cognitive Behavioral Therapy (REBT/CBT) Evaluation for Dysthymia in the Practice of Clinical Social Work at Primary Care Completed NCT02112708
46 Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial Completed NCT01583400
47 Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention Completed NCT01542957
48 Cognitive Behavioral Therapy for Early-Onset Depression Completed NCT00096642
49 Improving Depression Care for Elders: Coordinating Center Completed NCT01561105
50 Using Mental Health Telemetry to Predict Relapse and Re-hospitalization in Mood Disorders Completed NCT01882608

Search NIH Clinical Center for Dysthymic Disorder

Cochrane evidence based reviews: dysthymic disorder

Genetic Tests for Dysthymic Disorder

Anatomical Context for Dysthymic Disorder

MalaCards organs/tissues related to Dysthymic Disorder:

38
Brain, Testes, Spinal Cord

Publications for Dysthymic Disorder

Articles related to Dysthymic Disorder:

(show top 50) (show all 115)
# Title Authors Year
1
Changes in cytokine and chemokine expression distinguish dysthymic disorder from major depression and healthy controls. ( 27992767 )
2017
2
Cognitive Vulnerability in Patients with Generalized Anxiety Disorder, Dysthymic Disorder and Normal Individuals. ( 27045393 )
2016
3
Assessment of Quality of Life (QOL) in Obsessive Compulsive Disorder (OCD) and Dysthymic Disorder (DD): A Comparative Study. ( 26155540 )
2015
4
Relationship of quality of life with disability grade in obsessive compulsive disorder and dysthymic disorder. ( 25191009 )
2014
5
The re-labelling of dysthymic disorder to persistent depressive disorder in DSM-5: old wine in new bottles? ( 24270481 )
2014
6
An open treatment trial of duloxetine in elderly patients with dysthymic disorder. ( 25177490 )
2014
7
Frontoparietal function in young people with dysthymic disorder (DSM-5: Persistent depressive disorder) during spatial working memory. ( 24709020 )
2014
8
Dysthymic disorder in the elderly population. ( 24152873 )
2014
9
Add-on deep transcranial magnetic stimulation (dTMS) in patients with dysthymic disorder comorbid with alcohol use disorder: A comparison with standard treatment. ( 25140585 )
2014
10
Controlled randomized clinical trial of spirituality integrated psychotherapy, cognitive-behavioral therapy and medication intervention on depressive symptoms and dysfunctional attitudes in patients with dysthymic disorder. ( 24516853 )
2013
11
Efficacy of add-on deep transcranial magnetic stimulation in comorbid alcohol dependence and dysthymic disorder: three case reports. ( 23724355 )
2013
12
An examination of generalized anxiety disorder and dysthymic disorder by latent class analysis. ( 24020863 )
2013
13
Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study. ( 23466114 )
2013
14
L-acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. ( 23428336 )
2013
15
The categorisation of dysthymic disorder: can its constituents be meaningfully apportioned? ( 22835850 )
2012
16
Are there temperament differences between major depression and dysthymic disorder in adolescent clinical outpatients? ( 21839431 )
2012
17
Are there meaningful differences between major depressive disorder, dysthymic disorder, and their subthreshold variants? ( 22922240 )
2012
18
Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. ( 21869696 )
2011
19
Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. ( 21536001 )
2011
20
Trajectories of recovery of social and physical functioning in major depression, dysthymic disorder and double depression: a 3-year follow-up. ( 19945171 )
2010
21
The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. ( 21190638 )
2010
22
The impact of comorbid dysthymic disorder on outcome in personality disorders. ( 20728000 )
2010
23
The association of visuospatial working memory with dysthymic disorder in pre-pubertal children. ( 19607749 )
2010
24
Plasma levels of brain-derived neurotrophic factor and interleukin-6 in patients with dysthymic disorder: comparison with age- and sex-matched major depressed patients and healthy controls. ( 21312291 )
2010
25
Four cases of dysthymic disorder and general malaise successfully treated with traditional herbal (kampo) medicines: kamiuntanto. ( 21614161 )
2010
26
Escitalopram versus placebo in the treatment of dysthymic disorder. ( 21811192 )
2010
27
Impairment in psychosocial functioning associated with dysthymic disorder in the NESARC study. ( 20471093 )
2010
28
The effects of dysthymic disorder on health-related quality of life and disability days in persons with comorbid medical conditions in the general population. ( 19270471 )
2009
29
Do major depressive disorder and dysthymic disorder confer differential risk for suicide? ( 18842304 )
2009
30
Dysthymic disorder: forlorn and overlooked? ( 19724735 )
2009
31
The three-year naturalistic course of major depressive disorder, dysthymic disorder and double depression. ( 19042028 )
2009
32
Dysthymic disorder and double depression: prediction of 10-year course trajectories and outcomes. ( 17466334 )
2008
33
Comparison of prototypic cases of depressive personality disorder and dysthymic disorder. ( 18825775 )
2008
34
Plasma testosterone and dehydroepiandrosterone sulfate in male and female patients with dysthymic disorder. ( 17182106 )
2007
35
Comparison of psychosocial correlates in primary school age children with attention deficit/ hyperactivity disorder- combined type, with and without dysthymic disorder. ( 16755402 )
2006
36
Attention deficit hyperactivity disorder, combined type, dysthymic disorder and anxiety disorders: differential patterns of neurodevelopmental deficits. ( 16876876 )
2006
37
Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. ( 16648329 )
2006
38
Characteristics of internalizing and externalizing disorders in medication-naive, clinically referred children with attention deficit hyperactivity disorder, combined type and dysthymic disorder. ( 15860023 )
2005
39
Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. ( 15653941 )
2005
40
Dysthymic disorder contributes to oppositional defiant behaviour in children with Attention Deficit Hyperactivity Disorder, combined type (ADHD-CT). ( 15935256 )
2005
41
Mental health service use by patients with dysthymic disorder: treatment use and dropout in a 7 1/2-year naturalistic follow-up study. ( 16175754 )
2005
42
Longitudinal comparison of depressive personality disorder and dysthymic disorder. ( 16175753 )
2005
43
A growth curve analysis of the course of dysthymic disorder: the effects of chronic stress and moderation by adverse parent-child relationships and family history. ( 15612848 )
2004
44
Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients. ( 15013252 )
2004
45
Trait and state aspects of harm avoidance and its implication for treatment in major depressive disorder, dysthymic disorder, and depressive personality disorder. ( 15149288 )
2004
46
Citalopram in the treatment of dysthymic disorder. ( 15107656 )
2004
47
Psychopathology in the adolescent and young adult offspring of parents with dysthymic disorder and major depressive disorder. ( 15091300 )
2004
48
An open treatment trial of venlafaxine for elderly patients with dysthymic disorder. ( 15533993 )
2004
49
Which anxiety disorders may differentiate attention deficit hyperactivity disorder, combined type with dysthymic disorder from attention deficit hyperactivity disorder, combined type alone? ( 14511084 )
2003
50
Current therapeutic approaches for dysthymic disorder. ( 19810854 )
2003

Variations for Dysthymic Disorder

Expression for Dysthymic Disorder

Search GEO for disease gene expression data for Dysthymic Disorder.

Pathways for Dysthymic Disorder

GO Terms for Dysthymic Disorder

Biological processes related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.5 GATA3 HTR2A SLC6A4
2 phosphatidylinositol 3-kinase signaling GO:0014065 9.26 GATA3 HTR2A
3 smooth muscle contraction GO:0006939 9.16 HTR2A HTR7
4 vasoconstriction GO:0042310 8.96 HTR7 SLC6A4
5 circadian rhythm GO:0007623 8.8 CRY2 HTR7 SLC6A4

Molecular functions related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region sequence-specific DNA binding GO:0000976 9.26 CRY2 GATA3
2 neurotransmitter receptor activity GO:0030594 9.16 HTR2A HTR7
3 G-protein coupled serotonin receptor activity GO:0004993 8.96 HTR2A HTR7
4 serotonin binding GO:0051378 8.62 HTR2A HTR7

Sources for Dysthymic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....